Compare Five Below Inc (FIVE) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Moderna, Inc. — how do they compare? Five Below Inc trades at $193 (market cap $10.67B), while Moderna, Inc. trades at $63.09 (market cap $27.09B). The key difference: Moderna, Inc. is far larger — about 2.5× Five Below Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals.
| FIVE | MRNA | |
|---|---|---|
Market Cap | $10.67B | $27.09B |
Sector | Consumer Staples | Health |
52-Week High | $247.71 | $81.80 |
52-Week Low | $131.94 | $22.36 |
Enterprise Value | $11.56B | $23.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $200.59, up 3.87% today, with a bullish technical signal despite mixed moving averages. The company shows strong revenue growth, rising from $2.8B in 2022 to $3.88B in 2025, and has consistently beaten earnings expectations in recent quarters. Positive sentiment is driven by store expansion and digital marketing initiatives, with 60% of analysts rating it a Buy.
The outlook is favorable with a consensus price target of $252.09, implying 26% upside, supported by robust growth projections. Risks include competitive pressures and execution challenges in expansion. Net cash flow improved to $152M in 2025, but profit margins have fluctuated, requiring monitoring of cost management.
Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.
Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
